Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma

Gynecologic Oncology

Volumn 102, Issue 1, 2006, Pages 8-14

  McCreath, Wayne A ^a   Eisenhauer, Eric L ^a   Abu Rustum, Nadeem R ^a   Venkatraman, Ennapadam S ^a   Caceres, Aileen ^b   Bier, Rachel ^a   Huh, Jae ^a   Cho, Jae ^a   Barakat, Richard R ^a   Chi, Dennis S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Ovarian cancer; Prognostic factors; Second look surgery

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; PLATINUM; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE COURSE; EARLY INTERVENTION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY CARCINOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; SECOND LOOK SURGERY; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; EPITHELIAL CELLS; FEMALE; HUMANS; INFUSIONS, PARENTERAL; INJECTIONS, INTRAVENOUS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SECOND-LOOK SURGERY; TREATMENT OUTCOME;

EID: 33744911968     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.11.040     Document Type: Article

References (21)

1. Morrow C.P. An opinion in support of second-look surgery in ovarian cancer. Gynecol. Oncol. 79 (2000) 341-343
2. Rose P.G., Faulhaber P., Miraldi F., and Abdul-Karim F.W. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol. Oncol. 82 (2001) 17-21
3. Podratz K.C., and Cliby W.A. Second-look surgery in the management of epithelial ovarian carcinoma. Gynecol. Oncol. 55 (1994) S128-S133
4. Greer B.E., Bundy B.N., Ozols R.F., et al. Implications of second-look laparotomy (SLL) in the context of Gynecologic Oncology Group (GOG) protocol 158: a non-randomized comparison using an explanatory analysis. Gynecol. Oncol. 88 (2003) 156-157
5. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 351 (2004) 2519-2529
6. Barakat R.R., Almadrones L., Venkatraman E.S., et al. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol. Oncol. 69 (1998) 17-22
7. Barakat R.R., Sabatini P., Bhaskaran D., et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J. Clin. Oncol. 20 (2002) 694-698
8. Kaplan E.L., and Meier P. Nonparametric estimator from incomplete observations. J. Am. Stat. Assoc. 53 (1958) 457-481
9. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50 (1966) 163-170
10. Cox D.R. Regression models and life tables. J. R. Stat. Soc., B 34 (1972) 187-220
11. Bristow R.E., Tomacruz R.S., Armstrong D.K., and Trimble E.L. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 (2002) 1248-1259
12. Eisenkop S.M., Spirtos N.M., Friedman R.L., et al. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol. Oncol. 90 (2003) 390-396
13. Chi D.S., Franklin C.C., Levine D.A., et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol. Oncol. 94 (2004) 650-654
14. Rubin S.C., Randall T.C., Armstrong K.A., Chi D.S., and Hoskins W.J. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet. Gynecol. 93 (1999) 21-24
15. Dowdy S.C., Constantinou C.L., Hartmann L.C., et al. Long-term follow-up of women with ovarian cancer after positive second-look laparotomy. Gynecol. Oncol. 91 (2003) 563-568
16. MacGibbon A., Bucci J., MacLeod C., et al. Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma. Gynecol. Oncol. 75 (1999) 62-67
17. Bertucci F., Viens P., Delpero J.R., et al. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results. Bone Marrow Transplant. 26 (2000) 61-67
18. Hoskins W.J., Rubin S.C., Dulaney E., et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol. Oncol. 34 (1989) 365-371
19. Alberts D.S., Liu P.Y., Hannigan E.V., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 (1996) 1950-1955
20. Markman M., Bundy B.N., Alberts D.S., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007
21. Armstrong D.K., Bundy B.N., Baergen R., et al. Randomized phase III study of intravenous (IV) paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer: a Gynecologic Oncology Group trial. Proc. Am. Soc. Clin. Oncol. 12 (2002) 201a